LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-26. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
== Spy&Go affinity purification == Mutation of the catalytic glutamic acid residue (E77) in SpyCatcher to alanine stops isopeptide bond formation but does not prevent the initial non-covalent SpyTag/SpyCatcher association. This non-covalent SpyTag/SpyCatcher interaction has been utilized in the affinity purification of SpyTag-fused recombinant proteins. In this purification strategy, termed Spy&Go, resin-immobilized SpyCatcher is used to harvest SpyTag-fused proteins from cell culture supernatants or cell lysates. Non-specifically bound proteins are removed by washing the resin with a neutral buffer and the target protein eluted at neutral pH using high imidazole concentration. The Spy&Go affinity resin is based on SpyCatcher2.1 E77A S49C variant termed SpyDock. SpyDock can be expressed in E. coli as soluble protein, purified using Ni-NTA and anion-exchange resins and immobilized to iodoacetyl-activated agarose through the unpaired cysteine introduced by the S49C substitution. In neutral buffers with physiological salt concentration SpyDock binds to SpyTag- and SpyTag002-fused proteins with affinity in the high nanomolar range (Kd = 750 ± 50 nM for SpyTag, Kd = 73 ± 13 nM for SpyTag002). Affinity to SpyTag003 has not been reported, but requires harsher conditions to ensure full dissociation suggesting it binds tighter. SpyDock-bound proteins are eluted by incubating the resin with 2.5 M imidazole in neutral buffer. The SpyDock resin can be regenerated several times using consecutive washes with 4 M imidazole, 6 M guanidinium hydrochloride and 0.1 M NaOH.
== Quantum mechanical – thermodynamic modelling for surface area and porosity == Since 1980 two theories were worked on to explain adsorption and obtain equations that work. These two are referred to as the chi hypothesis, the quantum mechanical derivation, and excess surface work (ESW). Both these theories yield the same equation for flat surfaces:
=== Tracking of Cell Movement in Developmental Biology === EosFP has been used to track cell movements during embryonic development of Xenopus laevis. At the two-cell/ early gastrula stage, capped mRNA coding for a dimeric EosFP (d2EosFP) was injected into cells and locally photoconverted using fluorescence microscopy. These fluorescent embryos demonstrated the dynamics of cell movement during neurulation. EosFP was found in part of the notochord which shows the possibility of EosFP to be used in fate-mapping experiments.
Iraq's government made no secret that it would attack Israel if invaded. Prior to the war's start, in the aftermath of the failed US–Iraq peace talks in Geneva, Switzerland, a reporter asked Iraq's English-speaking foreign minister and deputy prime minister Tariq Aziz: "Mr. Foreign Minister, if war starts ... will you attack Israel?" His response was: "Yes, absolutely, yes." Five hours after the first attacks, Iraq's state radio broadcast declared that "The dawn of victory nears as this great showdown begins." Iraq fired eight missiles the next day. These missile attacks were to continue throughout the war. Iraq fired 88 Scud missiles during the war's seven weeks. Iraq hoped to provoke a military response from Israel. The Iraqi government hoped that many Arab states would withdraw from the Coalition, as they would be reluctant to fight alongside Israel. Following the first attacks, Israeli Air Force jets were deployed to patrol the northern airspace with Iraq. Israel prepared to militarily retaliate, as its policy for the previous 40 years had always been retaliation. However, President Bush pressured Israeli prime minister Yitzhak Shamir not to retaliate and withdraw Israeli jets, fearing that if Israel attacked Iraq, the other Arab states would either desert the coalition or join Iraq. It was also feared that if Israel used Syrian or Jordanian airspace to attack Iraq, they would intervene in the war on Iraq's side or attack Israel. The coalition promised to deploy Patriot missiles to defend Israel if it refrained from responding to the Scud attacks.
Sources: en.wikipedia.org
== Early life and education == Shawn was born in New York City to a Jewish family. His parents were journalist Cecille (née Lyon) and William Shawn, the longtime editor of The New Yorker. He has younger twin siblings: composer Allen Shawn, and Mary, who is autistic and lives in an institution. William was the son of emigrants from Central Europe. Shawn grew up on Manhattan's Upper East Side. He attended The Collegiate School on Manhattan's West Side before transferring to The Putney School, a private liberal arts high school in Putney, Vermont. After high school, he studied history at Harvard University, graduating in 1965 with a Bachelor of Arts. He then studied philosophy, politics and economics, as well as Latin, at Magdalen College, Oxford, originally intending to become a diplomat. He traveled to India as an English teacher on a Fulbright program.
=== Walter Bennett === Dr. Walter Bennett (voiced by Harry S. Robins) is a Black Mesa scientist. He is seen in Half-Life: Blue Shift. In Blue Shift, Dr. Bennett is seen fixing a battery in Dr. Rosenberg's office, along with Dr. Simmons. The three scientists soon get it fixed with the help of Barney Calhoun, and they start their teleportation out of Black Mesa. The four successfully make it out of the facility, making Dr. Bennett one of the few known survivors of the incident. They open the gates and start their journey to the outside world with an SUV. Dr. Bennett is briefly mentioned in Half-Life: Opposing Force. As Adrian Shephard traverses within Sector E of Black Mesa, he enters a testing laboratory where Xen specimens were being experimented on prior to the Resonance Cascade. He opens up a transmission intended for Dr. Bennett, revealing a hologram of a scientist talking about the results of an experiment conducted on a Barnacle, which was one of the Xen creatures being examined. Following the transmission, Shephard takes a nearby Barnacle specimen that was intended for Dr. Bennett to experiment on before the Resonance Cascade. Dr. Bennett's final fate is unknown.
In such low-temperature environments, there is potential for preserving the original hydrogen isotope signal over hundreds of millions of years. However, many rocks in geologic time have reached significant thermal maturity. Even by the onset of the oil window it appears that much of the hydrogen has exchanged. Recently, scientists have explored a silver lining: hydrogen exchange is a zero order kinetic reaction (for carbon bound hydrogen at 80–100°C, the half-times are likely 104–105 years). Applying the mathematics of rate constants would allow extrapolation to original isotopic compositions. While this solution holds promise, there is too much disagreement in the literature for robust calibrations.
ATP : NADH+H+ and ATP : FADH2 ratios during the oxidative phosphorylation appear to be not 3 and 2, but 2.5 and 1.5 respectively. Unlike in the substrate-level phosphorylation, the stoichiometry here is difficult to establish. ATP synthase produces 1 ATP / 3 H+. However the exchange of matrix ATP for cytosolic ADP and Pi (antiport with OH− or symport with H+) mediated by ATP–ADP translocase and phosphate carrier consumes 1 H+ / 1 ATP as a result of regeneration of the transmembrane potential changed during this transfer, so the net ratio is 1 ATP : 4 H+. The mitochondrial electron transport chain proton pump transfers across the inner membrane 10 H+ / 1 NADH+H+ (4 + 2 + 4) or 6 H+ / 1 FADH2 (2 + 4). So the final stoichiometry is 1 NADH+H+ : 10 H+ : 10/4 ATP = 1 NADH+H+ : 2.5 ATP 1 FADH2 : 6 H+ : 6/4 ATP = 1 FADH2 : 1.5 ATP ATP : NADH+H+ coming from glycolysis ratio during the oxidative phosphorylation is 1.5, as for FADH2, if hydrogen atoms (2H++2e−) are transferred from cytosolic NADH+H+ to mitochondrial FAD by the glycerol phosphate shuttle located in the inner mitochondrial membrane. 2.5 in case of malate-aspartate shuttle transferring hydrogen atoms from cytosolic NADH+H+ to mitochondrial NAD+ So finally we have, per molecule of glucose
=== Proposed long-range version === On June 26, 1972, a long-range version of the Il-86, the Il-86D (for Russian: "дальний"; transliterated: "dal’niy"; meaning "long-range"), was ordered into development by the Soviet cabinet. Design was completed in June 1976. The Il-86D would have had a marginally extended wing span, carried additional fuel, and had a range of some 8,500 km (4,600 nmi). Later announcements stated that a version of the Il-86D with Lotarev D-18 engines had entered development in March 1975. This version would have had a 147,500 kg (325,000 lb) empty weight, a 300,000 kg/660,000 lb maximum take-off weight, a fuel capacity of some 150,000 kg (330,000 lb), a wing area of 325 m2 (5,300 ft2), and a range of 10,200 km (5,500 nmi). It evolved into the Il-96.
Sources: en.wikipedia.org
== See also == Better Life Index Broad measures of economic progress Gross National Happiness Gross National Well-being Happiness economics Human Development Index Humanistic economics Job satisfaction Social determinants of health Social determinants of health in poverty Social determinants of mental health World Values Survey
=== Ground === Ground stainless steel belts are normally produced with surface roughness ranging from 0.4 μm down to 0.1 μm, with well-rounded edges, and developed for level and straight contour. Such belts are supplied in open lengths, with the ends prepared for welding on site, or in endless condition with a welded joint.
== Medical uses == Treatment of unstable angina (UA) and non-ST elevated myocardial infarction (NSTEMI), administered concurrently with aspirin DVT and pulmonary embolism prophylaxis in bed-ridden patients DVT prophylaxis in knee replacement surgery DVT prophylaxis in hip replacement surgery DVT prophylaxis in abdominal surgery Treatment of DVT with or without pulmonary embolism Treatment of DVT inpatient, with ST-segment elevation myocardial infarction (STEMI) Bridging treatment for those with INR below therapeutic range
=== Chemical toxicity === The chemical toxicity of depleted uranium is identical to that of natural uranium and about a million times greater in vivo than DU's radiological hazard, with the kidney considered to be the main target organ. Health effects of DU are determined by factors such as the extent of exposure and whether it was internal or external. Three main pathways exist by which internalization of uranium may occur: inhalation, ingestion, and embedded fragments or shrapnel contamination. Properties such as phase (e.g. particulate or gaseous), oxidation state (e.g. metallic or ceramic), and the solubility of uranium and its compounds influence their absorption, distribution, translocation, elimination and the resulting toxicity. For example, metallic uranium is less toxic compared to hexavalent uranium(VI) uranyl compounds such as uranium trioxide (UO3).
=== Legal status === The US Food and Drug Administration (FDA) refused its approval for use in combination with insulin for the treatment of type 1 diabetes. It is developed by Lexicon Pharmaceuticals. In May 2023, the US FDA approved sotagliflozin (Inpefa) to decrease the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk. The marketing authorization for sotagliflozin was withdrawn in the EU in August 2022, at the request of the marketing-authorization holder.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.